TrialCirculation2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Rick B Vega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.